Congestive Heart Failure Market Size (7MM) was valued at ~USD 6900 Million in 2023 and is projected to grow at a significant CAGR by 2034

The Congestive Heart Failure Market Size (7MM) was valued at ~USD 6900 Million in 2023 and is projected to grow at a significant CAGR during the study period (2020–2034). DelveInsight’s Comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the Congestive Heart Failure Market Landscape. By analyzing historical data, current Congestive Heart Failure Market Dynamics, and future projections, DelveInsight equips pharmaceutical companies, investors, and healthcare professionals with actionable intelligence to make informed strategic decisions, identify investment opportunities, optimize product positioning, and plan research and development initiatives effectively.

The Congestive Heart Failure Market is increasingly guided by biomarker-driven strategies. Congestive Heart Failure (CHF) is a chronic condition in which the heart is unable to pump blood efficiently enough to meet the body’s needs. As a result, blood and fluid can build up (or “congest”) in the lungs, legs, and other tissues, leading to symptoms such as shortness of breath, fatigue, swelling in the legs or abdomen, and reduced ability to exercise. CHF does not mean the heart has completely stopped working; rather, it indicates that the heart’s pumping function is weakened or stiff. It can develop due to underlying conditions like high blood pressure, coronary artery disease, or previous heart attacks. Over time, the condition may worsen if not properly managed, but with appropriate treatment—such as medications, lifestyle changes, and in some cases medical devices—many people can manage symptoms and improve their quality of life.

DelveInsight’s report, “Congestive Heart Failure Market Insights, Epidemiology, and Market Forecast-2034,” provides a comprehensive analysis of the Congestive Heart Failure Market landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions. Additionally, it examines Congestive Heart Failure Market Dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To know in detail about the Congestive Heart Failure Market Outlook, drug uptake, treatment scenario, and epidemiology trends, click here @ Congestive Heart Failure Market Forecast

Key Takeaways from Congestive Heart Failure Market Report

• The analysis of Congestive Heart Failure in the 7MM draws a clear scenario which showed that the patients with HFpEF have a larger proportion (i.e., ~50%) because the heart is not severely affected but keeps on working through medication or symptomatic treatment, whereas, in the case of HFrEF, the patient’s heart is majorly affected. With growing age, the pumping rate of the heart declines.
• In 2023, among all the four New York Heart Association (NYHA) Classes of heart failure, Class II accounted for around 45% of the total diagnosed heart failure cases in the 7MM.
• Maximum cases of heart failure fall in the age group of ≥ 60 years. In 2023, approximately 6.8 million cases of heart failure in the US belonged to this age group.
• In 2023, among EU4 and the UK, the largest number of heart failure cases were observed in Germany, followed by France and Spain, whereas the United Kingdom accounted for the smallest number of cases in the 7MM.
• The leading Congestive Heart Failure Companies such as Otsuka Pharmaceutical, Cytokinetics, AstraZeneca, Mesoblast, Bayer, Novo Nordisk, Lexicon Pharmaceuticals, Bristol-Myers Squibb, Intra-Cellular Therapies, Tenax Therapeutics, BioCardia, Eli Lilly and Company, and others.
• Promising Congestive Heart Failure Therapies such as Furosemide, Torsemide, Bumetanide, Dapagliflozin, AB-1002, OPC 131461 10mg group, Kcentra, and others.

Congestive Heart Failure Overview

Congestive Heart Failure (CHF) is a long-term heart condition in which the heart cannot pump blood effectively, causing fluid to accumulate in different parts of the body. This fluid buildup can lead to symptoms such as breathing difficulty, persistent tiredness, and swelling in the legs, ankles, or abdomen. Rather than a complete failure of the heart, CHF reflects a reduced ability of the heart to function properly, either because it has become too weak or too stiff. It commonly develops due to conditions like high blood pressure or heart disease, and it requires ongoing medical care and lifestyle management to control symptoms and prevent complications.

Get a Free sample for the Congestive Heart Failure Market Report @ https://www.delveinsight.com/sample-request/congestive-heart-failure-market

Key Factors in the Congestive Heart Failure Therapeutics Market

• Rising Global Disease Burden

The increasing prevalence of heart failure, driven by aging populations and lifestyle-related risk factors such as hypertension, obesity, and diabetes, is significantly expanding the patient pool.

• Growing Geriatric Population

Elderly individuals are more susceptible to heart failure, and the steady rise in the aging population is a major contributor to market growth.

• Advancements in Novel Drug Classes

Introduction of innovative therapies, including SGLT2 inhibitors, ARNI (angiotensin receptor-neprilysin inhibitors), and other targeted treatments, is transforming disease management and improving patient outcomes.

• Improved Diagnosis and Disease Awareness

Increased awareness among patients and healthcare providers, along with better diagnostic tools, is leading to earlier detection and higher treatment rates.

• Strong Pipeline and Ongoing Clinical Research

Continuous investment in research and development is resulting in a robust pipeline of next-generation therapies aimed at addressing unmet clinical needs.

• Rising Healthcare Expenditure

Increased healthcare spending across developed and emerging markets is enhancing access to advanced treatment options.

• Shift Toward Combination Therapies

Growing adoption of combination drug regimens is improving clinical outcomes and driving demand for multiple therapeutic classes.

Congestive Heart Failure Epidemiology Segmentation in the 7MM

The Congestive Heart Failure Market Report proffers epidemiological analysis for the study period 2022-2034 in the 7MM segmented into-

• Total Diagnosed Prevalent Cases of Heart Failure
• Gender-specific Cases of Heart Failure
• Ejection Fraction-specific Cases of Heart Failure
• NYHA Class-specific Cases of Heart Failure
• Type-specific Cases of Heart Failure (Acute and Chronic)
• Age-specific Cases of Heart Failure

Download the report to understand which factors are driving Congestive Heart Failure Epidemiology trends @ Congestive Heart Failure Epidemiology Forecast

Congestive Heart Failure Market Recent Breakthroughs

• In September 2025, Corstasis Therapeutics Inc. announced that the FDA approved ENBUMYST (bumetanide nasal spray) for the treatment of edema associated with congestive heart failure (CHF), as well as hepatic and renal diseases, including nephrotic syndrome in adults. ENBUMYST offers an enhanced outpatient therapeutic option for patients with cardiovascular and renal conditions.
• In September 2025, Aptar Pharma announced that its Unidose Liquid System has been selected as the delivery platform for Enbumyst™ (Bumetanide Nasal Spray) 0.5mg, recently approved by the U.S. FDA. Developed by Corstasis Therapeutics, Enbumyst™ is the first intranasal loop diuretic approved for the treatment of edema associated with congestive heart failure, liver and kidney diseases, including nephrotic syndrome, in adults.

Congestive Heart Failure Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential Congestive Heart Failure drugs recently launched in the Congestive Heart Failure market or expected to get launched during the study period. The analysis covers Congestive Heart Failure Market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Congestive Heart Failure Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Marketed Congestive Heart Failure Drugs

• ENTRESTO: Novartis

ENTRESTO combines a neprilysin inhibitor and an angiotensin II receptor blocker. In July 2015, the US FDA approved sacubitril with valsartan to reduce the risk of cardiovascular (CV) death and hospitalization in patients with Congestive Heart Failure (NYHA Class II-IV) associated with reduced ejection fraction and got expanded approval in October 2019 and February 2021 for pediatric patients aged ≥1 with symptomatic heart failure with systemic left ventricular systolic dysfunction and adult patients with Congestive Heart Failure respectively. ENTRESTO captured the major share of the Congestive Heart Failure market in 2022.

• JARDIANCE: Boehringer Ingelheim and Eli Lilly

JARDIANCE is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. The candidate is also being investigated in pivotal trials for heart failure post myocardial infarction and chronic kidney disease. In June 2021, Boehringer Ingelheim and Eli Lilly and Company announced that the European Commission had granted marketing authorization for JARDIANCE (empagliflozin) as a treatment for adults with symptomatic chronic HFrEF. Later in August 2021, it was approved by the US FDA. US FDA had granted Breakthrough Therapy designation based on results from the Phase III EMPEROR-Preserved trial. In the last year, JARDIANCE grabbed regulatory approval from all the major regulatory bodies (FDA, EMA, and PMDA) for the treatment of chronic heart failure in patients with HFpEF, thereby extending its targeted niche.

Emerging Congestive Heart Failure Drugs

• KERENDIA (finerenone): Bayer

Finerenone (BAY 94-8862) is an investigational novel, nonsteroidal, selective mineralocorticoid receptor antagonist (MRA) that has been shown to block many harmful effects of mineralocorticoid receptor (MR) overactivation, which is a major driver of kidney and heart damage. The drug has received regulatory approval in the US, Canada, and the EU to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, nonfatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease associated with type 2 diabetes. The drug is currently in a Phase III FINEARTS-HF trial in patients with heart failure and left ventricular ejection fraction greater or equal to 40%. FINEARTS-HF is currently the largest outcome trial investigating an MRA in HFpEF.

• MOUNJARO (tirzepatide): Eli Lilly and Company

Tirzepatide (LY3298176) is a once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that integrates the actions of both incretins into a single novel molecule. In May 2022, tirzepatide was approved by the US FDA as a treatment for adults with type 2 diabetes. Currently, the drug is in the Phase III stage of the clinical development program evaluating its safety and efficacy in participants with HFpEF and obesity. This drug has true potential and is expected to garner the maximum revenue by 2034.

To know more about Congestive Heart Failure Companies working in the treatment market, visit @ Congestive Heart Failure Clinical Trials and Therapeutic Assessment

Congestive Heart Failure Market Drivers

• Rising Disease Prevalence

Increasing cases of Congestive Heart Failure due to hypertension, diabetes, obesity, and coronary artery disease are expanding the patient pool.

• Growing Geriatric Population

The aging population is more susceptible to heart failure, significantly driving demand for long-term treatment options.

• Advancements in Novel Therapies

Introduction of innovative drug classes and combination therapies is improving clinical outcomes and boosting market growth.

• Improved Awareness and Early Diagnosis

Better screening practices and increased awareness are leading to earlier detection and higher treatment adoption.

• Rising Healthcare Expenditure

Increased healthcare spending is enhancing access to advanced therapies across both developed and emerging markets.

Congestive Heart Failure Market Barriers

• High Cost of Advanced Therapies

Innovative treatments for Congestive Heart Failure often come with significant costs, limiting accessibility, especially in low- and middle-income regions.

• Underdiagnosis and Late Diagnosis

Early-stage heart failure symptoms are often overlooked or misinterpreted, leading to delayed treatment and reduced market penetration of therapies.

• Complex Disease Management

CHF requires long-term, multi-drug regimens and lifestyle modifications, making treatment adherence challenging for many patients.

• Safety Concerns and Side Effects

Some therapies are associated with adverse effects, which can limit their use and reduce patient compliance.

• Stringent Regulatory Requirements

Cardiovascular drugs must meet rigorous clinical and safety standards, resulting in longer development timelines and delayed market entry.

• High Clinical Trial Costs and Failure Rates

Drug development in heart failure is expensive and carries a high risk of failure, discouraging some companies from investing.

Scope of the Congestive Heart Failure Market Report

• Coverage- 7MM
• Study Period- 2020-2034
• Congestive Heart Failure Companies- Otsuka Pharmaceutical, Cytokinetics, AstraZeneca, Mesoblast, Bayer, Novo Nordisk, Lexicon Pharmaceuticals, Bristol-Myers Squibb, Intra-Cellular Therapies, Tenax Therapeutics, BioCardia, Eli Lilly and Company, and others.
• Congestive Heart Failure Therapies- Furosemide, Torsemide, Bumetanide, Dapagliflozin, AB-1002, OPC 131461 10mg group, Kcentra, and others.
• Congestive Heart Failure Therapeutic Assessment: Congestive Heart Failure current marketed and emerging therapies
• Congestive Heart Failure Market Dynamics: Congestive Heart Failure market drivers and Congestive Heart Failure market barriers
• Congestive Heart Failure Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Congestive Heart Failure Unmet Needs, KOL’s views, Analyst’s views, Congestive Heart Failure Market Access and Reimbursement

Discover more about therapies set to grab the major Congestive Heart Failure Market Share @ Congestive Heart Failure Treatment Market

Table of Contents

1. Key Insights
2. Congestive Heart Failure Market Report Introduction
3. Congestive Heart Failure Executive Summary
4. Congestive Heart Failure Key Events
5. Congestive Heart Failure Epidemiology and Market Forecast Methodology
6. Congestive Heart Failure Market Overview at a Glance
7. Congestive Heart Failure Disease Background and Overview
8. Congestive Heart Failure Epidemiology and Patient Population
9. Congestive Heart Failure Patient Journey
10. Congestive Heart Failure Marketed Drugs
11. Congestive Heart Failure Emerging Drugs
12. Congestive Heart Failure: 7MM Analysis
13. Congestive Heart Failure Unmet Needs
14. Congestive Heart Failure SWOT Analysis
15. Congestive Heart Failure KOL Views
16. Congestive Heart Failure Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.